Table 3.
Microbiologically Documented Infections in 2 Treatment Groups
| Microbiologically documented infection (MDI) | PIP/TZO (n=59) | Ceftaz/Amikacin (n=59) | Excluded (n=5) |
|---|---|---|---|
| Hemoculture | 3 (5.1%) | 3 (5.1%) | 4 (80.0%) |
| -Staphylococcus epidermidis | 1 (1.7%) | 1 (1.7%) | 1 (20.0%) |
| -Escherichia coli | - | 1 (1.7%) | - |
| -Klebsiella pneumoniae | - | 1 (1.7%) | - |
| -Pseudomonas aeruginosa | 1 (1.7%) | - | 1 (20.0%) |
| -Enterobacter cloacae | 1 (1.7%) | - | - |
| -Morganella morganii | - | - | 1 (20.0%) |
| -Candida tropicalis | - | - | 1 (20.0%) |
| Urine culture | 6 (10.2%) | 5 (8.5%) | - |
| -Escherichia coli | 3 (5.1%) | - | - |
| -Enterococcus faecalis | - | 1 (1.7%) | - |
| -Enterococcus faecium | 2 (3.4%) | 1 (1.7%) | - |
| -Others* | 1 (1.7%) | 3 (5.1%) | - |
*Others are 1 Proteus mirabilis; 1 Klebsiella pneumoniae; 1 coagulase-negative Staphylococci and 1 Staphylococcus haemolyticus